20/20 BioLabs Posts Record Cancer Test Revenue, Expands Firefighter Screening — 20/20 Biolabs, Inc.

Event summary

OneTest™ revenue increased 47% year-over-year to $0.7 million in Q2 2026, accounting for 95.3% of total revenue.
Gross profit increased 87% to $0.3 million, with gross margin expanding to 41.7% from 30.5%.
State-funded firefighter cancer screening programs in Vermont and Maryland expected to generate over $1.0 million in revenue by year-end.
Cash position strengthened to $4.5 million as of June 30, 2026, with all convertible note debt eliminated during the quarter.

The big picture

20/20 BioLabs is capitalizing on the growing demand for early cancer detection, particularly through state-funded programs. The Company's strategic focus on expanding its OneTest™ platform into new markets and improving its financial position underscores its long-term play in the AI-powered diagnostic space. With a statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028, 20/20 BioLabs is positioning itself to benefit from expanding adoption and reimbursement opportunities.

What we're watching

Regulatory Strategy: How the growing body of real-world evidence from firefighter screenings will support FDA authorization and Medicare reimbursement for OneTest™.
Market Expansion: Whether the Company can sustain its momentum in new markets, including occupational health, military, and physician practices.
Financial Health: The pace at which 20/20 BioLabs can convert its Series E preferred financing into continued revenue growth and profitability.